Navigation Links
Reminding doctors which antibiotics to prescribe cuts C. difficile infection rates

-June 2001) and afterwards (July 2001-March 2003). A statistically significant drop in use of both cephalosporin and amoxicillin/clavulanate was observed after the narrow-spectrum policy came into effect. Prescriptions for antibiotics not specified by the policy did not change during this time, suggesting that the feedback and laminated card had had the desired targeted effect. There was also a significant fall in rates of CDI associated with the policy change.

"We have shown that introduction of a narrow-spectrum antibiotic policy, reinforced by feedback, was associated with significant changes in targeted antibiotics and a significant reduction in CDI", explains Dr Stone.

"National figures for CD and associated diseases showed the Royal Free to have the lowest rates of any teaching hospital. This success is largely being attributed to the antibiotic policies described in the paper", he adds.

The authors think their study could be a useful reference for other centres where cephalosporin use is higher than in the Royal Free. Compared with many other hospitals, cephalosporin use was already low at the beginning of the study and the intervention was still highly successful, indicating that even better results could be achieved in institutions where a greater reduction is desirable.

Dr Stone and colleagues used an interrupted time series design, which includes a single group of study subjects assessed before an after an intervention (in this case a change to antibiotic prescribing policy). This design includes measurement of many different variables both before and after the intervention, including a set of "control outcomes" that are not expected to change during the course of the study, to reduce the potential contribution of confounding factors to any result.

This design means the study provides stronger evidence than previous investigations of similar interventions. "Nearly all previous studies assessing interven
'"/>

Source:Oxford University Press


Page: 1 2 3 4

Related biology news :

1. Survey reveals women and doctors arent talking about HPV
2. Should doctors tell patients about expensive, unfunded drugs?
3. Efficiency, not more doctors, is the prescription for aging population
4. Stanford doctors advance in bid to turn mice stem cells into blood vessels
5. Patients and their doctors have different perceptions about HIV and its treatment
6. Free drug samples influence prescribing, say one in three doctors
7. Genes and biomarkers that allow doctors to choose the right therapy for the right patient
8. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
9. Overbearing colored light may reveal a second mechanism by which birds interpret magnetic signals
10. Bacteria which sense the Earths magnetic field
11. Researchers discover which organs in Antarctic fish produce antifreeze
Post Your Comments:
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) ... Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition ... reading feature with the iPhone 5S. It is currently ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB SM ... (GCP) audit to confirm its adherence to current U.S. ... HITLAB to conduct regulated smart device and smart phone ... and research quality. "HITLAB is determined to ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... disorders are almost five times more common among boys than ... $15 million National Institutes of Health (NIH) grant awarded to ... (ACE) research program. Led by principal investigator Kevin ... is part of a $100 million National Institutes of Health ...
... - Influenza outbreaks in the United States typically begin ... spread in seasonal waves across geographic zones. But the ... to the next has baffled scientists. In a ... Obscure Consequence," Elena Naumova, Ph.D., professor of civil and ...
... SAN FRANCISCO, Sept. 6, 2012 -- After last year,s accidental ... State researchers are conducting an elaborate experiment to learn more ... are tagging infected bees with tiny radio trackers, and monitoring ... hive on top of the Hensill Hall biology building on ...
Cached Biology News:Influenza research: Can dynamic mapping reveal clues about seasonality? 2SF State biologists tag 'zombees' to track their flight 2SF State biologists tag 'zombees' to track their flight 3
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 27 Alfacell Corporation (OTC Bulletin Board: ACEL) today ... the U.S. Food and Drug Administration (FDA) to discuss ... the ONCONASE rolling New Drug Application (NDA) for the ... the pre-NDA meeting, the FDA provided guidance to the ...
... for Tuesday, February 3, 2009 SAN DIEGO, Jan. 27 ... announced today that the Company will report its fourth ... market closes on Tuesday, February 3, 2009. Neurocrine will ... discuss its financial results and provide a Company update ...
... in Shortest Period of TimeWASHINGTON, Jan. 27 ... in targeted therapies that utilize personalized medicine to ... by the Deloitte Center for Health Solutions found ... to produce a positive return on investment across ...
Cached Biology Technology:Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results 2Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 2Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 3Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 4
... Monoclonal Mouse Antibody to Cytokeratin 5 ... is a high molecular weight, basic type ... and the superficial cell layers of stratified ... epithelia and in mesothelial cells and mesothelioma. ...
...
Aldolase A (N-15)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Biology Products: